David Rubin, OD
Optometrist · Venice, FLNPI 1982682423
Payments from drug & device makers
Across 230 payments — averaging $40.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Bausch & Lomb Americas Inc.$948
- Amgen$600
- Sun Pharmaceutical Industries Inc.$586
- Tarsus Pharmaceuticals, Inc.$527
- Alcon$471
- plus $4K from 29 others
Across 54 payments — averaging $36.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$2K
What the payments were for
- Speaking & faculty fees$3163%
- Food & beverage$8,94197%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,764 |
| Bausch & Lomb Americas Inc. | 16 | $948 |
| Amgen(2 entities) | 10 | $600 |
| Sun Pharmaceutical Industries Inc. | 11 | $586 |
| Tarsus Pharmaceuticals, Inc. | 15 | $527 |
| Alcon | 12 | $471 |
| Notal Vision, Inc. | 11 | $457 |
| Sight Sciences, Inc. | 5 | $451 |
| Coopervision Inc. | 3 | $307 |
| Dompe US, Inc. | 5 | $271 |
| Eyevance Pharmaceuticals LLC | 3 | $259 |
| Alimera Sciences, Inc. | 12 | $251 |
| Aerie Pharmaceuticals, Inc. | 4 | $232 |
| Harrow Eye, LLC | 5 | $218 |
| Apellis Pharmaceuticals, Inc. | 4 | $195 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $194 |
| ANI Pharmaceuticals, Inc. | 6 | $162 |
| Maculogix, Inc. | 1 | $141 |
| Novartis | 2 | $135 |
| Glaukos Corporation | 2 | $134 |
| Eyepoint US, Inc. | 1 | $127 |
| Spark Therapeutics, Inc. | 1 | $122 |
| Johnson & Johnson | 1 | $104 |
| Coherus Oncology, Inc. | 3 | $102 |
| Optovue, Inc. | 1 | $93 |
| Rxsight Inc | 1 | $88 |
| Kala Pharmaceuticals, Inc. | 4 | $82 |
| Astellas Pharma US Inc | 2 | $52 |
| Sandoz | 1 | $45 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Biotissue Holdings Inc. | 2 | $31 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Heidelberg Engineering, Inc. | 1 | $18 |
| Oasis Medical, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$608
- XIIDRA$483
- CEQUA$366
- OMNI(R) SURGICAL SYSTEM (US)$279
- TEPEZZA$240
- DURYSTA$231
- Flarex$149
- Precision7$144
- AdaptDx$141
- TEARCARE SYSTEM$140
- MyDay Contact Lens$129
- YUTIQ$127
- VEVYE$125
- TRYPTYR$125
- Syfovre$122
- LUXTURNA$122
- XDEMVY$122
- ScoutPro Osmolarity System$114
- KXL System$107
- BIOTRUE ONE DAY$105
How this compares
$9,257 in reported general payments places this provider in the 90th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 195 | $81,002 |
| RestasisCyclosporine | 37 | $42,882 |
| Cyclosporine | 23 | $24,248 |
| MieboPerfluorohexyloctane/Pf | 32 | $23,547 |
| CombiganBrimonidine Tartrate/Timolol | 51 | $15,935 |
| XiidraLifitegrast | 11 | $11,582 |
| VyzultaLatanoprostene Bunod | 13 | $6,961 |
| Alphagan PBrimonidine Tartrate | 24 | $5,178 |
| Latanoprost | 490 | $4,867 |
| Travoprost | 24 | $4,365 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 222 | $3,535 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $3,519 |
| Timolol Maleate | 203 | $2,850 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,766 |
| Loteprednol Etabonate | 14 | $1,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,764 | $144,997307 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $948 | $42,09056 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $194 | $4,49725 claims |
| Eyevance Pharmaceuticals LLCFlarex | $259 | $1,34411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Venice
- Joseph SowkaVenice$105K
- Michael KynnJacksonville$4.5M
- Christine HalodaJacksonville$3.1M
- Bradley GieddWinter Park$2.5M
- Christopher PearsonLongwood$2.5M
- Mark PerryOrlando$1.6M
- Bryan StamJacksonville Beach$1M
- Oksana SovaJacksonville$841K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$781K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.